| (Values in U.S. Thousands) | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Novelion Therapeutics Inc (NVLN.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Novelion Therapeutics Inc is a biopharmaceutical company. It is engaged in developing patient care facility and providing services for people suffering from rare diseases like lipodystrophy, leber congenital amaurosis, and retinitis pigmentosa. Novelion, Aegerion, JUXTAPID, LOJUXTA, MYALEPT and MYALEPTA are the registered trademarks of the company.